(+)-JQ1

Name: (+)-JQ1
Brand: Selleck Chemicals
SKU: S7110
Rating: 5 (295 reviews)

For research use only.

Catalog No.S7110

295 publications

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.

Selleck's (+)-JQ1 has been cited by 295 publications

Cell, 2021, S0092-8674(21)00354-8

PubMed: 33811809 ( click the link to review the publication )

Cell, 2020, 182(4):992-1008.e21

PubMed: 32710817 ( click the link to review the publication )

Nat Genet, 2020, 52(4):408-417

PubMed: 32203462 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):512-526

PubMed: 29533787 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(29)e2104013118

PubMed: 34253616 ( click the link to review the publication )

Biomaterials, 2021, 275:120958

PubMed: 34130142 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

Elife, 2021, 10e63810

PubMed: 33835029 ( click the link to review the publication )

Oncogene, 2021, 40(22):3799-3814

PubMed: 33958721 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):106

PubMed: 33741018 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009091

PubMed: 33411730 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3906

PubMed: 34359807 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):691-703

PubMed: 33509905 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:682561

PubMed: 34179011 ( click the link to review the publication )
Biochim Biophys Acta Mol Basis Dis, 2021, 1867(12):166267

PubMed: 34508829 ( click the link to review the publication )

J Virol, 2021, JVI.02124-20

PubMed: 33762408 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):375

PubMed: 34261480 ( click the link to review the publication )

Bioorg Chem, 2021, 115:105238

PubMed: 34390970 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12190

PubMed: 34251762 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00467-7

PubMed: 33891939 ( click the link to review the publication )

Prostate, 2021, 81(9):508-520

PubMed: 33955576 ( click the link to review the publication )

Transl Oncol, 2021, 14(10):101181

PubMed: 34298440 ( click the link to review the publication )

J Antibiot (Tokyo), 2021, 10.1038/s41429-021-00433-2

PubMed: 34163027 ( click the link to review the publication )

J Mol Neurosci, 2021, 10.1007/s12031-021-01861-3

PubMed: 34462884 ( click the link to review the publication )

Tissue Cell, 2021, 72:101555

PubMed: 33957539 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(2):530-545

PubMed: 33575085 ( click the link to review the publication )

Clin Transl Med, 2021, 11(7):e495

PubMed: 34323404 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):51

PubMed: 33980863 ( click the link to review the publication )

Commun Biol, 2021, 4(1):878

PubMed: 34267311 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108749

PubMed: 33596420 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 16;7(7):1902926

PubMed: 32274304 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202021450

PubMed: 33310900 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2246.2020

PubMed: 33109736 ( click the link to review the publication )

Cancer Res, 2020, canres.1030.2020

PubMed: 32934021 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )
J Exp Clin Cancer Res, 2020, 39(1):261

PubMed: 33239043 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2668

PubMed: 32962010 ( click the link to review the publication )

Cell Death Dis, 2020, 17;11(4):239

PubMed: 32303673 ( click the link to review the publication )

Br J Cancer, 2020, 4

PubMed: 32362655 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 6;19:109-123

PubMed: 31837602 ( click the link to review the publication )

J Mol Cell Biol, 2020, 11;12(5):359-371

PubMed: 31565729 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(5):4547-4557

PubMed: 32163373 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(1):397-415

PubMed: 31901895 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Carcinogenesis, 2020, 41(9):1282-1293

PubMed: 31826234 ( click the link to review the publication )

Epigenetics, 2020, 22:1-13

PubMed: 32164487 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00497-6

PubMed: 32166583 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3503-3515

PubMed: 32726482 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Oncogenesis, 2020, 9(3):33

PubMed: 32157097 ( click the link to review the publication )

ACS Chem Biol, 2020, 17;15(4):895-903

PubMed: 32176478 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(7):1004-1017

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:565820

PubMed: 33134168 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(2):1650-1657

PubMed: 31821686 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6873

PubMed: 32961679 ( click the link to review the publication )
Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00570-8

PubMed: 33311600 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Int J Biol Macromol, 2020, 164:3204-3220

PubMed: 32860796 ( click the link to review the publication )

Front Pharmacol, 2020, 8;11:618

PubMed: 32457617 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Exp Cell Res, 2020, 24:112034

PubMed: 32339606 ( click the link to review the publication )

Med Sci Monit, 2020, 8;26:e923411

PubMed: 32266878 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0160

PubMed: 32703768 ( click the link to review the publication )

Cancer Cell, 2020, 37(4):584-598

PubMed: 32220301 ( click the link to review the publication )

Front Oncol, 2020, 9:1471

PubMed: 31993368 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01393-x

PubMed: 32747750 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002

PubMed: 32175692 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33222

PubMed: 32683685 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Inflamm Regen, 2020, 40:25

PubMed: 33072227 ( click the link to review the publication )

Blood Adv, 2020, 4(20):5062-5077

PubMed: 33080008 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):673

PubMed: 32826850 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )
EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Genome Res, 2019, 29(10):1659-1672

PubMed: 31515287 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(14):4748-4758

PubMed: 31731295 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )

J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Can J Physiol Pharmacol, 2019, 97(11):1028-1034

PubMed: 31330113 ( click the link to review the publication )

Nucleic Acids Res, 2019, gkz1139

PubMed: 31822909 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0682-7

PubMed: 31862959 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

JScholarship, 2019, None

PubMed: None ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354.e6

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )
EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29988031 ( click the link to review the publication )

Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )

Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )
Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190682

PubMed: 29298347 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )

J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2017, 37(8):1513-1523

PubMed: 28473439 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )
Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )

J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )
Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )

Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )

Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Circ Res, 2015, 117(6):525-35

PubMed: 26224795 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )
Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVPCT5VPOjVyL{WwNE8yODByIH7N	M{j1NlI1NzR6L{eyJIg>	M3P2d2ROW09?	NX\YdXBqcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>?	MlTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MEe4PFEoRjJ4N{C3PFgyRC:jPh?=
BCPAP	NVT2VWZ5S2WubDDWbYFjcWyrdImgRZN{[Xl?	MVqyOVAwPTByL{GwNFAhdk1?	MoWwNlQwPDhxN{KgbC=>	NVn1bHRwTE2VTx?=	MX3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	NETv[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkewO\|g5OSd-Mk[3NFc5QDF:L3G+
K1	MV;D[YxtKEO7Y3zlJGF{e2G7	M{DXW\|I2OC93MECvNVAxOCCwTR?=	NVG0VZdNPzJiaB?=	NVjMTnA6TE2VTx?=	MlnSZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn	NUXzTZZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3NFc5QDFpPkK2O\|A4QDhzPD;hQi=>
BCPAP	M4fsO2NmdGxiQ4njcIUhSXO\|YYm=	NIrxW2QzPTBxNUCwM\|ExODBibl2=	NH3HVpU4OiCq	NXznbWRvTE2VTx?=	M123SYFzemW\|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG\|ZR?=	MnfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MEe4PFEoRjJ4N{C3PFgyRC:jPh?=
Hep3B	NUfJWXJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP2bGdLOC1zMDFOwG0>	MlXhOUBl	MYTEUXNQ	MUnJR\|UxRTBwMEig{txO	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
HCCLM3	M335c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2wMVExKM7:TR?=	MkOxOUBl	NEjKOm1FVVOR	NETDUYVKSzVyPUCuNVQh\|ryP	NYLEcG5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
HuH7	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;RUXlqOC1zMDFOwG0>	Mlq5OUBl	MnHMSG1UVw>?	NXLjd2VCUUN3ME2wMlIyKM7:TR?=	NV3GUJRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
HepG2	M3izOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnuW\|cxNTFyIN88US=>	Mm\ZOUBl	NYno[GJwTE2VTx?=	NX3tRm5{UUN3ME2wMlM1KM7:TR?=	M3:4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
SMMC7721	M1ThTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLYNE0yOCEQvF2=	MV:1JIQ>	NVzK[2hWTE2VTx?=	MUTJR\|UxRTBwNEGg{txO	NY\1doI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
BEL7402	NInLblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXywMVExKM7:TR?=	MnrZOUBl	MlnWSG1UVw>?	NX3QfnFIUUN3ME2wMlQ4KM7:TR?=	MkTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
MHCC97H	NIHKO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfTflI1OC1zMDFOwG0>	M{nVXFUh\A>?	NGHtS\|ZFVVOR	M2ntUmlEPTB;MD60NUDPxE1?	NHrueoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
Hep3B	NXvHbGxQS2WubDDDfYNt\SCDc4PhfS=>	NES0dY8xNjFxMD61M\|IvPSEQvF2=	M2HIZlQ5KGh?	MYDEUXNQ	NWqzVmFYdGWjZIOgeI8h[SC\|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy\|IHnuJJN2[i2JMTDwbIF{\cLi	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
HCCLM3	Mm[xR4VtdCCFeXPs[UBCe3OjeR?=	NFHWOpQxNjFxMD61M\|IvPSEQvF2=	NULSWGE5PDhiaB?=	NG\4V2dFVVOR	M4Tvd4xm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
Hep3B	NXL6Z41xSXCxcITvd4l{KEG\|c3H5	MnO0NE4yNzBwNT:yMlUh\|ryP	M1nP[lQ5KGh?	MY\EUXNQ	M37JcYFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO\|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF?	MkLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
HCCLM3	MmPWRZBweHSxc3nzJGF{e2G7	NVXlboR6OC5zL{CuOU8zNjVizszN	MWi0PEBp	M4nDdmROW09?	NUXzeo1m[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG\|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG\|bTDmdo9uKG2rdH;jbI9v\HKrYR?=	NULPem94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
A549	NVLKNYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVewMlEuOTBizszN	NFW0TpM4OiCq		MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MmPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MUWyNlUoRjJ4NEG1NlI2RC:jPh?=
H157	NX7ufItOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfZcXQxNjFvMUCg{txO	NUHK[5VmPzJiaB?=		MojHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NVLkcG1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H1299	NYfN[5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmflNE4yNTFyIN88US=>	MYe3NkBp		MlXqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M{KzNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
A549	NXLSPJE3TnWwY4Tpc44hSXO\|YYm=	NXq4WVhqOS9{LkWvOUDPxE1?	NY\CNHB5OTJiaB?=		NXvMS5RkyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?=	NXjNPJNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H1299	NWW4eGY3TnWwY4Tpc44hSXO\|YYm=	NGDDcJEyNzJwNT:1JO69VQ>?	MYSxNkBp		NVqyeohYyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?=	NXHuW3JFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H157	M3zFVWZ2dmO2aX;uJGF{e2G7	MVWxM\|IvPS93IN88US=>	NXjkdJR{OTJiaB?=		NX:xW3Bo\GWlcnXhd4VlKESUNDDlfJBz\XO\|aX;u	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRzNUKyOUc,OjZ2MUWyNlU9N2F-
H1299	NECyWIJHfW6ldHnvckBCe3OjeR?=	NUjyTWV2OS9{LkWvOUDPxE1?	M{XQcVEzKGh?		NIC4OFRl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRzNUKyOUc,OjZ2MUWyNlU9N2F-
C8161	MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2DH[VAuOiEQvF2=	NUi4b\|VXPCCm	MVrEUXNQ	NFqxV5Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3G2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Mel285	MoP1R4VtdCCYaXHibYxqfHliQYPzZZk>	NITlTGIxNTJizszN	NFHsfpY1KGR?	MXPEUXNQ	M3LwWoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MlvPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel290	NFLBO2JE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX2wMVIh\|ryP	NVW1XGZNPCCm	MknGSG1UVw>?	NVPzdY1F\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MnnaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
92.1	NH\DNIZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MYiwMVIh\|ryP	MXS0JIQ>	NX;sfHlqTE2VTx?=	M3vqNIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Omm1.3	NE\OVplE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MoDMNE0zKM7:TR?=	M13mTlQh\A>?	NEfSNWtFVVOR	M1X3N4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel202	M4HSSGNmdGxiVnnhZoltcXS7IFHzd4F6	MVSwMVIh\|ryP	MkT0OEBl	NHToT5pFVVOR	M121b4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUfsZXh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Mel270	NGHl[HlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3fEN\|AuOiEQvF2=	MWS0JIQ>	MlPFSG1UVw>?	MYjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NG\BUpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Omm1	Mn\GR4VtdCCYaXHibYxqfHliQYPzZZk>	NUezTmxNOC1{IN88US=>	NV\UeHZEPCCm	MnfRSG1UVw>?	NXTpWWxr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFL1e4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
92.1	MXfBdI9xfG:\|aYOgRZN{[Xl?	NXz2eHAzPTByIH7N	MmLLOFghcA>?	M1v2emROW09?	NWfLPY1KcW6mdXPld{BieG:ydH;zbZM>	M1SzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Omm1.3	NVzWbZJESXCxcITvd4l{KEG\|c3H5	Mnr5OVAxKG6P	M{jmOFQ5KGh?	MVnEUXNQ	MlLubY5lfWOnczDhdI9xfG:\|aYO=	MmXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
92.1	M4q2UGNmdGxiQ4njcIUhSXO\|YYm=	M1vuSlUxOCCwTR?=	Ml7BNlQwPDhxN{KgbC=>	M{jKPWROW09?	NIXjNIJqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{KyN{c,OjZ\|OUeyNlM9N2F-
Omm1.3	MkLQR4VtdCCFeXPs[UBCe3OjeR?=	MlS0OVAxKG6P	MoXBNlQwPDhxN{KgbC=>	MmT2SG1UVw>?	M3nVT4lv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi	NGPMWpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
A549	NUnWfIVOTnWwY4Tpc44hSXO\|YYm=	MlzsNVAxNzRyMD:xNFAxKG6P	M3TVdlI1KGh?		MmLDeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	M1\WUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGyNVk6Lz5{NkKxNlE6QTxxYU6=
MCF-7	M3zlWWZ2dmO2aX;uJGF{e2G7	M4fBbFExOC92MECvNVAxOCCwTR?=	MXiyOEBp		NI\1c4F2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMkG5PUc,OjZ{MUKxPVk9N2F-
HEK293	NY\EVnc2TnWwY4Tpc44hSXO\|YYm=	MXOxNFAwPDByL{GwNFAhdk1?	MXSyOEBp		NWrtWGVkfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?=	MkHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUKxPVkoRjJ4MkGyNVk6RC:jPh?=
858	Mo\YR4VtdCCYaXHibYxqfHliQYPzZZk>	NYrwdYYzOC1zIN88US=>	M2jCUVUh\A>?	MVzEUXNQ	MlHz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[zN\|MoRjJ4MkC2N\|M{RC:jPh?=
DDR2L63V	M{jDd2NmdGxiVnnhZoltcXS7IFHzd4F6	NX\ucHc1OC1zIN88US=>	MXm1JIQ>	MorpSG1UVw>?	NEPNcHhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXzabW9yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY{OzNpPkK2NlA3OzN\|PD;hQi=>
BE(2)-C	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NWDIRm9COSEQvF2=	MYqxMVQh\A>?		MlW3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
IMR-32	MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3jUU\|Eh\|ryP	MlzONU01KGR?		NVmweZJ{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	NUm0Z3hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOlc1PjRpPkK2NFY4PDZ2PD;hQi=>
JF	NIjI[XpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MYOxJO69VQ>?	NHXHbGMyNTRiZB?=		MUTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=>	MoDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
BE(2)-M17	NFK0OGFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MUGxJO69VQ>?	Ml\XNU01KGR?		NEj2fFFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NV\6WnduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOlc1PjRpPkK2NFY4PDZ2PD;hQi=>
SK-N-SH	NIjqTGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVqxJO69VQ>?	NGnhdZcyNTRiZB?=		NF;tdnll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
SK-N-DZ	NVfjWoZvS2WubDDWbYFjcWyrdImgRZN{[Xl?	NVL6N3hlOSEQvF2=	MlXVNU01KGR?		NEnDRZBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
HMC-1.1	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUi1MVUxODBibl2=	MWW0PEBp	M37QcGROW09?	NVPr[mtVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NUi2THNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
HMC-1.2	NXfseFFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fOd\|UuPTByMDDuUS=>	M2TnVFQ5KGh?	MV\EUXNQ	NE\QRWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M4e3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
ROSA KIT WT	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\WboY2NTVyMECgcm0>	Mn\ROFghcA>?	M4\zOGROW09?	MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NX7sRpp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
ROSA KIT D816V	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr5OU02ODByIH7N	NYnDV49bPDhiaB?=	M2S2SGROW09?	MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NF\jfII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVMxOyd-Mk[wOVU{ODN:L3G+
HMC-1.1	MmfNRZBweHSxc3nzJGF{e2G7	NVPZSnMzOjByLUWwNFAhdk1?	Ml\3OFghcA>?	M4DrTWROW09?	NHvmbZZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NG\yXVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVMxOyd-Mk[wOVU{ODN:L3G+
HMC-1.2	NEPwd3ZCeG:ydH;zbZMhSXO\|YYm=	MYKyNFAuPTByMDDuUS=>	NIXDeW41QCCq	M4T3O2ROW09?	M2TWPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
ROSA KIT WT	NFjmd\|RCeG:ydH;zbZMhSXO\|YYm=	MlPSNlAxNTVyMECgcm0>	MYK0PEBp	MVHEUXNQ	MoH0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NU\hVXZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
ROSA KIT D816V	MlfURZBweHSxc3nzJGF{e2G7	NW[1U45mOjByLUWwNFAhdk1?	NXjyXGtYPDhiaB?=	MWHEUXNQ	MoTQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
494H	NIi1fHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGTUOWo4OiCq	M4X1dmROW09?	NWHqNJl2UUN3ME2wMlEzOsLzMD6wNFQh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
493H	NYrLeVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUCw[WJuPzJiaB?=	MkPDSG1UVw>?	MWnJR\|UxRTBwMES3xtExNjByOTFOwG0>	NXfERmtMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
716H	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NE\KNWs4OiCq	M1nLRmROW09?	MYjJR\|UxRTBwMkGyxtExNjB\|NDFOwG0>	NEDzbWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
148I	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFjhdY04OiCq	MVnEUXNQ	NUnMR\|lUUUN3ME2wMlI5PMLzMD6wN\|Uh\|ryP	NF7Lb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
98Sc	NGnDNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3W2OlczKGh?	Mo\BSG1UVw>?	NH\GWmRKSzVyPUCuNVE2yrFyLkCwOEDPxE1?	Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
89R	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnubZI2PzJiaB?=	M3\uW2ROW09?	NXnvTFRCUUN3ME2wMlEzPsLzMD6wNFMh\|ryP	NVPHSnVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
494L	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkHpO\|IhcA>?	M{i0UGROW09?	M2rie2lEPTB;MD6zNVfDuTBwMEGyJO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
493L	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUnFS2lbPzJiaB?=	NHPacI9FVVOR	M{XNW2lEPTB;MD6wOVDDuTBwMEGxJO69VQ>?	NV\lcmhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
148L	NGf3VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrwO\|IhcA>?	MXTEUXNQ	NIP2XXFKSzVyPUCuNVQ3yrFyLkCxO{DPxE1?	M1TtPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
98L	M2KzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUnrWI1zPzJiaB?=	NXX0[4NITE2VTx?=	NG[3UWpKSzVyPUCuN\|A6yrFyLkCyPUDPxE1?	NWr3c2JSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
OS17	M3Gzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NICzbJU4OiCq	NVXmTHhpTE2VTx?=	NXvxWotCUUN3ME2wMlA4QcLzMD6wNFMh\|ryP	M2LzXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS9	NF7MXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIPSUHo4OiCq	NYPSc4Y6TE2VTx?=	MXjJR\|UxRTBwNEC2xtExNjB{ODFOwG0>	NEj3XnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
MG63	M4HKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlPhO\|IhcA>?	NE\pRo1FVVOR	MVvJR\|UxRTBwMUG0xtExNjB{NTFOwG0>	MoTXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
SAOS2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnTEO\|IhcA>?	NWPlNm9{TE2VTx?=	MUjJR\|UxRTBwMkG3xtExNjByMzFOwG0>	M4XKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
U2OS	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXi3NkBp	M4HiTGROW09?	MV7JR\|UxRTBwMUm4xtExNjByODFOwG0>	MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
SJSA-1	Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoTpO\|IhcA>?	MnjsSG1UVw>?	NX6wWHJ2UUN3ME2wMlExOMLzMD6wNVAh\|ryP	M1jXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
494H	MmPVRZBweHSxc3nzJGF{e2G7	Mn:xNE4zPS9yLkWvNU4xKM7:TR?=	MnvUNlQhcA>?	M3zYd2ROW09?	MYrpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	NVLzVGZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
148I	NVHWdGVJSXCxcITvd4l{KEG\|c3H5	NXT2dotHOC5{NT:wMlUwOS5yIN88US=>	M4rCblI1KGh?	MkjySG1UVw>?	NInJdGJqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G\|cHHz[U0{yqB?	NIjYOpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
OS17	NX3DVI1vSXCxcITvd4l{KEG\|c3H5	Ml7YNE4zPS9yLkWvNU4xKM7:TR?=	MYKyOEBp	MnvYSG1UVw>?	NYTYd5RTcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li	NHnkOZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
494H	MnKwRZBweHSxc3nzJGF{e2G7	Mnv0NgKBkc7:TR?=	NYjyWJlmPDhiaB?=	MX;EUXNQ	M4XxUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=>	MmXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	MVfBdI9xfG:\|aYOgRZN{[Xl?	M3GwRVHjiIoQvF2=	MlzBOFghcA>?	M3jabWROW09?	Mm\wbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	M1LNT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS17	MX7BdI9xfG:\|aYOgRZN{[Xl?	NXzo[oxsOeLCid88US=>	NUS2[2c5PDhiaB?=	MknjSG1UVw>?	MlXSbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
MOLM13	MkLHRZBweHSxc3nzJGF{e2G7	MnHZNlUxKG6P	M1zVUFQ5KGh?	NWLwW\|ZLTE2VTx?=	MVnpcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ?	NH60c3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1N\|gzPSd-MkWwOVM5OjV:L3G+
MV4-11	MUHBdI9xfG:\|aYOgRZN{[Xl?	MkjoNlUxKG6P	MnnYOFghcA>?	NXjDOXRVTE2VTx?=	MYrpcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ?	MnTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MOLM13	MXfGeY5kfGmxbjDBd5NigQ>?	MXSyOVAhdk1?	NEDzN4gzPCCq	M{j2RWROW09?	NVTQUIho\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ	NUL5dVM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVM5OjVpPkK1NFU{QDJ3PD;hQi=>
MV4-11	M4rLeGZ2dmO2aX;uJGF{e2G7	MX2yOVAhdk1?	NVW5fXM6OjRiaB?=	NEPmZ2dFVVOR	NXfrfYU5\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ	M4DXOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPFI2Lz5{NUC1N\|gzPTxxYU6=
MOLM13	MonDRZBweHSxc3nzJGF{e2G7	M3fGZVI2OCCwTR?=	Mln5OFghcA>?	NYfzV4JoTE2VTx?=	NHj4dlhqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk	M3XRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPFI2Lz5{NUC1N\|gzPTxxYU6=
MV4-11	MlTnRZBweHSxc3nzJGF{e2G7	MkPZNlUxKG6P	NEDKT2Q1QCCq	NX;JbVYxTE2VTx?=	NUXWOJdScW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?=	NHXJcok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1N\|gzPSd-MkWwOVM5OjV:L3G+
Hela	M37qNmNmdGxiVnnhZoltcXS7IFHzd4F6	NIrmbGExNTVyMDDuUS=>	MV[3NkBp	MULEUXNQ	NV;ud\|FJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
HBL-1	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MX2wMVUxOCCwTR?=	NHfMOJQ4OiCq	MWLEUXNQ	M3zZNoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
HLY-1	MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NXm5SFBGOC13MECgcm0>	MlPEO\|IhcA>?	MmnxSG1UVw>?	NHfKcW9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NETFcnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly3	NYDReYRrS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYSwMVUxOCCwTR?=	M1TkOVczKGh?	NXS3OohiTE2VTx?=	M3TXO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFXQXpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly10	M4XOc2NmdGxiVnnhZoltcXS7IFHzd4F6	Mn7ONE02ODBibl2=	M1LuPFczKGh?	NED3S5NFVVOR	M2TXXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NVnsZ4dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-4	MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYTGPXFROC13MECgcm0>	NHrrVpQ4OiCq	Mn\MSG1UVw>?	MXTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-5	NXL4XmVSS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmXyNE02ODBibl2=	MnPYO\|IhcA>?	MmToSG1UVw>?	M4nqfIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NYDmeGVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-6	MlXSR4VtdCCYaXHibYxqfHliQYPzZZk>	MWmwMVUxOCCwTR?=	MV23NkBp	MYPEUXNQ	MkWx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	NYn4[3VwS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGjYSIsxNTVyMDDuUS=>	MX63NkBp	NHHzXoxFVVOR	MYnk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MoHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
RC-K8	NGTWOldE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXewMVUxOCCwTR?=	M1z1[\|czKGh?	MVnEUXNQ	MlrE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	Ml31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly8	NIS1O4hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1G4N\|AuPTByIH7N	MVe3NkBp	MlX0SG1UVw>?	M2fQcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCL-Ly18	Mn32R4VtdCCYaXHibYxqfHliQYPzZZk>	MVOwMVUxOCCwTR?=	NH21WWU4OiCq	NWLTN3hKTE2VTx?=	MXvk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M4nJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
OCI-Ly3	NFvsNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6yZWgyPzJxMkWwM\|UxOCCwTR?=	NH76NpQzNzdiZB?=	M2L0VWROW09?	MnHqbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	Mlz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly8	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWD4SHlkOTd{L{K1NE82ODBibl2=	M3HxTFIwPyCm	NFTPS4pFVVOR	MYjpcoR2[2W\|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi	NYHwemhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-4	M2mzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTBTW0yPzJxMkWwM\|UxOCCwTR?=	NYn1XHJLOi95IHS=	NUTqW5NITE2VTx?=	MUXpcoR2[2W\|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	NVvBTnZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOxO\|IwOjVyL{WwNEBvVQ>?	M{LkPFIwPyCm	NITxcHBFVVOR	NWLPeo1ScW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCI-Ly3	NGDscnRCeG:ydH;zbZMhSXO\|YYm=	MX[xO\|IwOjVyIH7N	MmflO4Q>	M{WwWmROW09?	NETkUWxqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	NFzKdnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly8	MYLBdI9xfG:\|aYOgRZN{[Xl?	NGr1XIQyPzJxMkWwJI5O	M3fG[Vdl	M33DU2ROW09?	NUXj[YJicW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	NWjSemZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-4	NYTtXFJGSXCxcITvd4l{KEG\|c3H5	NV3kR444OTd{L{K1NEBvVQ>?	NIrPb3Y4\A>?	MlX2SG1UVw>?	MULpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	MkHDRZBweHSxc3nzJGF{e2G7	Mkf3NVczNzJ3MDDuUS=>	M1jvTVdl	MVXEUXNQ	NWrIToF1cW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	NWDmb41kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
Rosetta2 DE3	NFf2emRHfW6ldHnvckBie3OjeR?=				M2e1UGtlKD1iMD6wNFYzKM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	M{S2bGZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		NVvNfIRxOzBibXnudy=>		NGTU[mdMcSB;IECuNFA3PiEQvF2=	NUjvXJFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MknuSpVv[3Srb36gZZN{[Xl?				MVLL[EA:KDBwMEC2O{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NWD4UGRXTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		NInxSnM{OCCvaX7z		NWf5OopVU2liPTCwMlAxPzZizszN	NUfYeYQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NGfqc5JHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		NYTkPVZkOzBibXnudy=>		MkjQT4khRSByLkCwPFkh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	Ml;vSox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		M{TUdFMxKG2rboO=		NILsOWJMcSB;IECuNFExPyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	MlSzSpVv[3Srb36gZZN{[Xl?				MoPrT4QhRSByLkCxNVch\|ryP	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
MV4-11	MnPPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M37xclczKGh?		Ml7VTWM2OCB;IECuNFEzKM7:TR?=	NV\ibmVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
Rosetta2 DE3	NUiweVl{Tmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		Mnf1N\|AhdWmwcx?=		MkHiT4khRSByLkCxNkDPxE1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
VCaP	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NWi2cY8yOTJiaB?=		NVzQOnJzUUN3MDC9JFAvODF{IN88US=>	NV;lW4dTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
Rosetta2 DE3	MWfGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		MkC1N\|AhdWmwcx?=		NF;3NppMcSB;IECuNFEzPSEQvF2=	NXHX[\|JjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M1jHemZ2dmO2aX;uJIF{e2G7				NGT0XI5M\CB;IECuNFEzQCEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NWjZWFdtTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		NXHZfZp[OzBibXnudy=>		MXHLbUA:KDBwMEGzNkDPxE1?	MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MnG0SpVv[3Srb36gZZN{[Xl?				MmfzT4QhRSByLkCxN\|Yh\|ryP	NV76SGJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NUnURmNoTnWwY4Tpc44h[XO\|YYm=				Ml\NT4QhRSByLkCxOFch\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	M1v0S2ZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		MlK0N\|AhdWmwcx?=		MXnLbUA:KDBwMEG0PUDPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
TY82	M2nNW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NIj4S2k4OiCq		NUTVS\|FYUUN3MDC9JFAvODF6IN88US=>	M1zpSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUi2O\|E5Lz5{OEW4OlcyQDxxYU6=
MM1S	M1;VR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MYS3NkBp		M1uzO2lEPTBiPTCwMlAyQSEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
MM1S	NYK1d41US3m2b4TvfIlkcXS7IHHzd4F6		NX;lO4tRPzJiaB?=		Ml\qTWM2OCB;IECuNFIh\|ryP	NGT4[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
HT-29	M2fsTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MYmxNkBp		MXnJR\|UxKD1iMD6wNkDPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV\|NUC0OUc,Ojh3M{WwOFU9N2F-
MV4-11	NUXiOJpJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mmf6O\|IhcA>?		NXq5UI9[UUN3MDC9JFAvODJ\|IN88US=>	MknOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUm0NlgoRjJ3NUW5OFI5RC:jPh?=
MV4-11	Mm\WR5l1d3SxeHnjbZR6KGG\|c3H5		NWDQOJlEPCCmYYnz		NXKyNWNtUUN3MDC9JFAvODJ2IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
MV4-11	MnHDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX3NSGhMPCCmYYnz		MXLJR\|UxKD1iMD6wNlQh\|ryP	NXTH[YhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NH;Mc25HfW6ldHnvckBie3OjeR?=		M3;6eVMxKG2rboO=		NF\lNGlKSzVyIE2gNE4xOjh5IN88US=>	NHPrdFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
NALM16	NH7l[oNEgXSxdH;4bYNqfHliYYPzZZk>		MoXROUBl[Xm\|		NWjWR492TUN3MDC9JFAvODNizszN	MkXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
BL21(DE3)-R3-pRARE2	MnXISpVv[3Srb36gZZN{[Xl?		MVSzNEBucW6\|		M3K2W2lEPTBiPTCwMlA{OyEQvF2=	NYjpdVdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVU4OjNpPkK4NVk2PzJ\|PD;hQi=>
BL21(DE3)	NGnEPGpHfW6ldHnvckBie3OjeR?=				NWLWUnhoU2RiPTCwMlA{PCEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
Rosetta2 DE3	NH34VHpHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		NVi3Xo1{OzBibXnudy=>		MXHJR\|UxKD1iMD6wN\|U4KM7:TR?=	NVTFe2JlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NXPXNWV7Tmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		MnzzN\|AhdWmwcx?=		NXHjVHl5UUN3MDC9JFAvODR{MjFOwG0>	Mnf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
Rosetta2 DE3	MXjGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		MWmzNEBucW6\|		MWDJR\|UxKD1iMD6wOFY4KM7:TR?=	NID2VZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N\|Q5Pyd-Mki0OlM1QDd:L3G+
MOLM13	Mmm3R5l1d3SxeHnjbZR6KGG\|c3H5		NFK5XIw1KGSjeYO=		NFzObIVKSzVyIE2gNE4xPTZizszN	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
MOLM13	NXfuZlNzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1PDXFQh\GG7cx?=		NUezWGQ3UUN3MDC9JFAvODV4IN88US=>	NYfjVoZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
HL60	NXjlVll1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M1TvW\|czKGh?		MnTITWM2OCB;IECuNFYh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
HL60	NXrXfGpOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXzOdHdtOyCmYYnz		MnnvS2M2OCB;IECuNFYh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3N{C5PUc,Ojl4NUewPVk9N2F-
NALM6	NX\LSYxyS3m2b4TvfIlkcXS7IHHzd4F6		MW[1JIRigXN?		MlTGSWM2OCB;IECuNFYh\|ryP	Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=
Raji	MX;GeY5kfGmxbjDhd5NigQ>?				Ml73TWM2OCB;IECuNFYh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
Raji	NYG4XlZtTnWwY4Tpc44h[XO\|YYm=		NUfNTXVKPCCq		NIjDVHNKSzVyIE2gNE4xPjlizszN	NYnIO413RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PThpPkK0PVAxPzV6PD;hQi=>
MM1S	MorlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnvGO\|IhcA>?		M2XVWGlEPTBiPTCwMlA3QTFizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N\|U9N2F-
BL21 (DE3)-codon plus-RIL	NFPVSmdHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		NYDsfJk1[nliZnz1c5Jme2OnbnPlJIFvcXOxdILvdJkh[XO\|YYm=		NWriUnpsUUN3MDC9JFAvODdizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
22Rv1	NXLV[\|NkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NYnhc2h3QTZiaB?=		M{OxfWlEPTBiPTCwMlA4OSEQvF2=	NVy0Zm04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
22Rv1	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M1zKZlEzKGh?		NWW2bFFkUUN3MDC9JFAvODdzIN88US=>	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
MV4-11	M1O4OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				M1zUb2lEPTBiPTCwMlA4OiEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7NUeyN{c,OjhzOUW3NlM9N2F-
BL21(DE3)-R3-pRARE2	MoXiSpVv[3Srb36gZZN{[Xl?		NHS3Rpc{OCCvaX7z		MnXwTWM2OCB;IECuNFc4KM7:TR?=	NXP5[nFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
BL21(DE3)-R3-pRARE2	MX7GeY5kfGmxbjDhd5NigQ>?		MXmzNEBucW6\|		NXTGVXJ1UUN3MDC9JFAvODd5IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7NUeyN{c,OjhzOUW3NlM9N2F-
BL21(DE3)-R3-pRARE2	NVPndpg2TnWwY4Tpc44h[XO\|YYm=		M4rXRVMxKG2rboO=		NITIWXJKSzVyIE2gNE4xPzdizszN	NWXmWJZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|Y5OzRpPkK5O\|c3QDN2PD;hQi=>
MV4-11	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=		M3HCcFI1KGh?		MkjsS2k2OCB;IECuNFgh\|ryP	MnHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUGzOlMoRjJ4MUmxN\|Y{RC:jPh?=
MV411	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M4m0VlczKGh?		NWHX[VlHUUN3MDC9JFAvODhizszN	NHjNeHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOFUyOyd-MkizNVQ2OTN:L3G+
TY82	NG\x[HRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mm\tO\|IhcA>?		NXPNWYI6UUN3MDC9JFAvODhyODFOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N\|U9N2F-
HL60	NIDLS5hHfW6ldHnvckBie3OjeR?=		MVmyOEBp		NGG3SndKSzVyIE2gNE4xQDZizszN	NFnMc2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+
697	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=		NUDVTGxUPSCmYYnz		MlnvSWM2OCB;IECuNFkh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
Loucy	MoG3R5l1d3SxeHnjbZR6KGG\|c3H5		MYC1JIRigXN?		Mn\zSWM2OCB;IECuNFkh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
BL21(DE3)	MnTxSpVv[3Srb36gZZN{[Xl?				MX\L[EA:KDBwMEmyJO69VQ>?	M1i2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
BL21(DE3)-R3-pRARE2	MnvnSpVv[3Srb36gZZN{[Xl?				MmjOT4QhRSByLkGg{txO	M1q1eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUm1NFA4Lz5{OEW5OVAxPzxxYU6=
HT-29	NWX3XIxkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFLFOnI4OiCq		Mk\zTWM2OCB;IECuNVA1KM7:TR?=	NVX1T\|BPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVk1OjhpPkK1OVU6PDJ6PD;hQi=>
MM1S	M3PHc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4HOOlczKGh?		M1PiRWlEPTBiPTCwMlExQSEQvF2=	MkfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUm0NlgoRjJ3NUW5OFI5RC:jPh?=
LNCAP cells	NG\QbWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				MVTJR\|UxKD1iMD6xNFk3KM7:TR?=	NYOyR3hxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
T cells	MWTGeY5kfGmxbjDhd5NigQ>?		MmW2NlQhcA>?		NIfpdmlKSzVyIE2gNE4yOSEQvF2=	M{Xyd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G0OVE{Lz5{OEOxOFUyOzxxYU6=
HL60	NXPkOm5ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEP0U\|E4OiCq		NVrSfm1{UUN3MDC9JFAvOTFizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh4OUG5OEc,OjZ6NkmxPVQ9N2F-
BL21(DE3)	M4nZ[WZ2dmO2aX;uJIF{e2G7				NGTIWJBKSzVyIE2gNE4yOiEQvF2=	MnPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
BL21(DE3)	NWr6UXJiTnWwY4Tpc44h[XO\|YYm=		NIizXZUzNjViaB?=		MVHJR\|UxKD1iMD6xNkDPxE1?	NF:zWYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
H1299	NH;GXYhHfW6ldHnvckBie3OjeR?=		NELOS5UzPCCq		MmPSSWM2OCB;IECuNVU{KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl2OUWyNUc,Ojh7NEm1NlE9N2F-
HD-MB03	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=		NFXsRWM2KGSjeYO=		NX74fXRsTUN3MDC9JFAvOTZizszN	NUXmZ4pxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
LNCAP	M4fwS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MVm5OkBp		NYrLUm1SUUN3MDC9JFAvOTZizszN	Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
Hs578T	M3jCbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NILDcW8yOiCq		NYDu[IZ7UUN3MDC9JFAvOTZizszN	M4q0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
MV4-11	NXXab5NVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NI\Ne4QyOiCq		NUT1XXUzUUN3MDC9JFAvOTZizszN	NXvPPHc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|AxOjRpPkK5NVcxODJ2PD;hQi=>
LNCAP	NYny[WVVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		Mk\GNVIhcA>?		NFi1WmhKSzVyIE2gNE4yPiEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO3NUc,Ojl3NEGzO\|E9N2F-
C4-2B	M13RVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MVq5OkBp		Mm\HTWM2OCB;IECuNVkh\|ryP	M3LKRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
C4-2B	M1roemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NWCzfoF5OTJiaB?=		MkXuTWM2OCB;IECuNVkh\|ryP	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
Vero E6	MVTBcpRqfmm{YXygZYN1cX[rdImgZZN{[Xl?		MXm0PEBp		MmLGTWM2OCB;IECuNVkzPzVizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OjN3M{i1PUc,OzJ\|NUO4OVk9N2F-
MCF7	NWjXWmQ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3nj[\|EzKGh?		NXGyT5FkUUN3MDC9JFAvOiEQvF2=	NI\RR\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
MV4-11	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?				NXXtUGlqUUN3MDC9JFAvOjRizszN	NGHRT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G0Nlc2OSd-MkexOFI4PTF:L3G+
MV4-11	NEjvPYlEgXSxdH;4bYNqfHliYYPzZZk>		MV63NkBp		Mmq0TWM2OCB;IECuNlQzKM7:TR?=	M4rXS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3NFEyLz5{M{WxO\|AyOTxxYU6=
MX1	M1TpeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NHHidVI4OiCq		M{n6cmVEPTBiPTCwMlI2PCEQvF2=	M4rXOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUS5OVIyLz5{OEm0PVUzOTxxYU6=
HT-29	NFn5b4NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXPm[2s3PzJiaB?=		NVzifmc4UUN3MDC9JFAvOjhizszN	NXS1cmF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
HFL1	MmnjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXzqcYpQOTJiaB?=		NXTuWnVDUUN3MDC9JFAvOjlizszN	MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
MDA-MB-231	NWPmPXFNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlzRN{Bl[Xm\|		M4HpVWdEPTBiPTCwMlMh\|ryP	NX7XZ4x1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
MV4-11	NULZOFhpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEHSR4U1QCCq		NXXE[YptTUN3MDC9JFAvOzNzMUOg{txO	NXvIeY4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PVUxODdpPkK4OVk2ODB5PD;hQi=>
K562	MkfmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MYTJR\|UxKD1iMD62OEDPxE1?	M4XEbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUSyO\|UyLz5{N{G0Nlc2OTxxYU6=
HL60	NFizdZBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MknkOFghcA>?		NEHRWXBGSzVyIE2gNE44PDF\|MTFOwG0>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV7NUCwO{c,Ojh3OUWwNFc9N2F-
NCI-H1975	NHv5WoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NH;aeGUyOiCq		NXr2[YR3UUN3MDC9JFEvOjNizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
SAE	MUXGeY5kfGmxbjDhd5NigQ>?		NILaR\|c1KGh?		M1nGc2lEPTBiPTCxMlM5KM7:TR?=	NYf6PVNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
SAE	M4mwOmZ2dmO2aX;uJIF{e2G7		M1j3WVQhcA>?		NYO5SphyUUN3MDC9JFEvPDlizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ2OUe0NUc,Ojl4NEm3OFE9N2F-
SAE	MkHkSpVv[3Srb36gZZN{[Xl?		MoPGOEBp		M1rKXmlEPTBiPTCxMlUyKM7:TR?=	NF;VVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
U2OS	NXPVOG5JSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MkD4NVIhcA>?		NXXKZYxxUUN3MDC9JFEvPjJizszN	M4XjblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
SAE	MlzWSpVv[3Srb36gZZN{[Xl?		M{TZSVQhcA>?		M2e0OGlEPTBiPTCxMlY{KM7:TR?=	NYnPWFlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
A549	NUfrNoVRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NIT4flMyOiCq		MW\JR\|UxKD1iMT62O{DPxE1?	NYXNV292RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MCF7	NIr0NnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUL3[FI{OyCmYYnz		NEjWfJRISzVyIE2gNU44KM7:TR?=	NVrJZpFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
DU145	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NF\ISIE6PiCq		MYDJR\|UxKD1iMj61NkDPxE1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
DU145	M2XDPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MX[xNkBp		NEnaUIhKSzVyIE2gNk42OiEQvF2=	NUHMPYhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
T47D	NEXWTZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXftZnVsOyCmYYnz		NHW2PWlISzVyIE2gNk45KM7:TR?=	Ml[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=
PC3	NEDjZpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkiyPVYhcA>?		M1jtWmlEPTBiPTCzMlAyKM7:TR?=	MnXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
PC3	NGfuOm5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3zRelEzKGh?		M4W0eWlEPTBiPTCzMlAyKM7:TR?=	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
HeLa	NG\QXodCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MUixNkBp		MVTJR\|UxKD1iMz63OkDPxE1?	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
K562	NF;QVGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnzoN{Bl[Xm\|		NGrVVW1ISzVyIE2gN{45KM7:TR?=	NG\vSFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+
A2780	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUXhV\|JLOyCmYYnz		MWLHR\|UxKD1iNDFOwG0>	NEK0Spk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+
HL60	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		M4nK[lI1KGh?		Ml3ITWM2OCB;IEWuN{DPxE1?	NEjjcFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K2Olk6QSd-MkeyOlY6QTl:L3G+
MV4-11	MmL0R5l1d3SxeHnjbZR6KGG\|c3H5		MnTlNlQhcA>?		NYnMN4RiUUN3MDC9JFYvPCEQvF2=	NUHO[\|VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyOlY6QTlpPkK3NlY3QTl7PD;hQi=>
K562	M3TjfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWS3NkBp		M3\tcmlEPTBiPTC5MlEzKM7:TR?=	MlzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUS1NVMoRjJ6M{G0OVE{RC:jPh?=
OVCAR5	M17rNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYXGSHdwOyCmYYnz		NFjZNotISzVyIE2gNVIh\|ryP	NHX1fIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Water	Insoluble
	Ethanol	'91 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1